Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases. The company licensed from Takeda the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (PCAB) marketed since 2015 in Japan, and has been developing it as a treatment for certain GI disorders. Branded as Voquezna®, the product has been approved in the US since 2022 for the treatment of Helicobacter pylori (H. pylori) infectios and since 2023 for the treatment and maintenance of healing for erosive gastroesophageal reflux disease (GERD). Phathom has been listed on NASDAQ since 2019 with the ticker symbol PHAT.